Association between androgen deprivation therapy and risk of dementia

JAMA Oncology

Volumn 3, Issue 1, 2017, Pages 49-55

  Nead, Kevin T ^a,b   Gaskin, Greg ^a   Chester, Cariad ^a   Swisher McClure, Samuel ^b   Leeper, Nicholas J ^a   Shah, Nigam H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; PROPENSITY SCORE; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SENILE DEMENTIA; SENSITIVITY ANALYSIS; TREATMENT DURATION; ADULT; ANTAGONISTS AND INHIBITORS; CANCER REGISTRY; CANCER STAGING; CHEMICALLY INDUCED; CLASSIFICATION; COMPLICATION; ELECTRONIC HEALTH RECORD; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS; VERY ELDERLY;

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DEMENTIA; ELECTRONIC HEALTH RECORDS; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM;

EID: 85013128265     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3662     Document Type: Article

References (42)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
2. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011; 365(2):107-118.
3. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360 (9327):103-106.
4. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8): 1615-1624.
5. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93(6):2042-2049.
6. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60(3) (suppl 1):7-11.
7. D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17): 2420-2425.
8. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.
9. Gonzalez BD, Jim HS, Booth-Jones M, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021-2027.
10. McGinty HL, Phillips KM, Jim HS, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271-2280.
11. Nead KT, Gaskin G, Chester C, et al. Androgen deprivation therapy and future Alzheimer’s disease risk. J Clin Oncol. 2016;34(6):566-571.
12. Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-beta peptide. JAMA. 2001;285(17):2195-2196.
13. Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav. 2013;63(2): 301-307.
14. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-1524.
15. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City Study. Diabetes Care. 2009;32(1):169-174.
16. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.e2.
17. LePendu P, Iyer SV, Bauer-Mehren A, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther. 2013;93(6):547-555.
18. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653.
19. Wu ST, Liu H, Li D, et al. Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysis. J Am Med Inform Assoc. 2012;19(e1):e149-e156.
20. Harkema H, Dowling JN, Thornblade T, Chapman WW. ConText: an algorithm for determining negation, experiencer, and temporal status from clinical reports. J Biomed Inform. 2009; 42(5):839-851.
21. St Germaine-Smith C, Metcalfe A, Pringsheim T, et al. Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology. 2012;79(10):1049-1055.
22. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154(7):635-641.
23. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334-357.
24. Morton RA Jr. Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994;44(5):637-645.
25. Extermann M, Aapro M, Bernabei R, et al; Task Force on CGA of the International Society of Geriatric Oncology. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241-252.
26. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31(5): 380-402.
27. Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462-469.
28. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192-201.
29. Frakt AB. An observational study goes where randomized clinical trials have not. JAMA. 2015;313 (11):1091-1092.
30. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578-3587.
31. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5): 1097-1106.
32. Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age-related testosterone depletion and the development of Alzheimer disease. JAMA. 2004; 292(12):1431-1432.
33. Hogervorst E, Combrinck M, Smith AD. Testosterone and gonadotropin levels in men with dementia. Neuro Endocrinol Lett. 2003;24(3-4): 203-208.
34. Carcaillon L, Brailly-Tabard S, Ancelin ML, et al. Low testosterone and the risk of dementia in elderly men: impact of age and education. Alzheimers Dement. 2014;10(5 suppl):S306-S314. doi:10.1016/j.jalz.2013.06.006
35. Cherrier MM, Matsumoto AM, Amory JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64(12):2063-2068.
36. D’Amico AV, Braccioforte MH, Moran BJ, Chen MH. Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24(1):85-89.
37. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349(9046):151-154.
38. Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem. 2001;77(5): 1319-1326.
39. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci. 2002;3(6):433-442.
40. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12(6):612-619.
41. Correa DD, Satagopan J, Baser RE, et al. APOE polymorphisms and cognitive functions in patients with brain tumors. Neurology. 2014;83(4):320-327.
42. Rowland JH, Bellizzi KM. Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol. 2014;32(24): 2662-2668.